Xencor Inc. | Income Statement

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
10,172.00
9,520.00
27,762.00
87,520.00
35,711.00
40,603
SG&A Expense
19,981.00
25,095.00
43,741.00
63,514.00
86,893.00
116,522
EBIT
10,520.00
16,457.00
17,092.00
22,540.00
53,166.00
79,170
Unusual Expense
48,556.00
-
1,246.00
-
-
200
Non Operating Income/Expense
16.00
11.00
1,081.00
15.00
416.00
141
Interest Expense
1,213.00
9.00
13.00
-
-
-
Pretax Income
60,259.00
16,422.00
17,592.00
24,616.00
49,388.00
70,409
Income Tax
-
-
-
991.00
463.00
-
Consolidated Net Income
84,506.00
16,422.00
17,592.00
23,625.00
48,925.00
70,409
Net Income
84,506.00
16,422.00
17,592.00
23,625.00
48,925.00
70,409
Net Income After Extraordinaries
84,506.00
16,422.00
17,592.00
23,625.00
48,925.00
70,409
Net Income Available to Common
84,506.00
16,422.00
17,592.00
23,625.00
48,925.00
70,409
EPS (Basic)
3.85
0.52
0.45
0.56
1.05
1.31
Basic Shares Outstanding
2,472.60
31,390.60
39,015.10
41,267.30
46,817.80
53,942.10
EPS (Diluted)
3.85
0.52
0.45
0.56
1.05
1.31
Diluted Shares Outstanding
15,645.80
31,390.60
39,015.10
42,388.90
46,817.80
53,942.10
EBITDA
9,809.00
15,575.00
15,979.00
24,006.00
51,182.00
75,919
Non-Operating Interest Income
14.00
33.00
1,840.00
2,091.00
4,194.00
9,102
Other After Tax Income (Expense)
144,765.00
-
-
-
-
-

About Xencor

View Profile
Address
111 West Lemon Avenue
Monrovia California 91016
United States
Employees -
Website http://www.xencor.com
Updated 07/08/2019
Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I.